-+ 0.00%
-+ 0.00%
-+ 0.00%

MEDICUS PHARMA PUBLISHES ABRIDGED FINAL PHASE 2 SKINJECT® CLINICAL STUDY REPORT (CSR) RESULTS IDENTIFYING 200 ΜG D-MNA PATCH AS THE LEAD DEVELOPMENT DOSE

Reuters·09/10/2026 11:30:07

Please log in to view news